Radiogenomic explainable AI with neural ordinary differential equation for identifying post-SRS brain metastasis radionecrosis.

Journal: Medical physics
PMID:

Abstract

BACKGROUND: Stereotactic radiosurgery (SRS) is widely used for managing brain metastases (BMs), but an adverse effect, radionecrosis, complicates post-SRS management. Differentiating radionecrosis from tumor recurrence non-invasively remains a major clinical challenge, as conventional imaging techniques often necessitate surgical biopsy for accurate diagnosis. Machine learning and deep learning models have shown potential in distinguishing radionecrosis from tumor recurrence. However, their clinical adoption is hindered by a lack of explainability, limiting understanding and trust in their diagnostic decisions.

Authors

  • Jingtong Zhao
    Duke University Medical Center, Durham, North Carolina.
  • Eugene Vaios
    Duke University Medical Center, Durham, North Carolina.
  • Zhenyu Yang
    College of Electronic Engineering (College of Artificial Intelligence), South China Agricultural University, Guangzhou, China.
  • Ke Lu
    University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China. Electronic address: luk@ucas.ac.cn.
  • Scott Floyd
    Duke University Medical Center, Durham, North Carolina.
  • Deshan Yang
    Department of Radiation Oncology, Washington University School of Medicine, 4921 Parkview Place, Campus Box 8224, St. Louis, MO, 63110, USA.
  • Hangjie Ji
    Department of Mathematics, North Carolina State University, Raleigh, North Carolina, USA.
  • Zachary J Reitman
    Duke University Medical Center, Durham, North Carolina.
  • Kyle J Lafata
    Department of Radiology, Duke University School of Medicine, Durham, NC, USA. kyle.lafata@duke.edu.
  • Peter Fecci
    Duke University Medical Center, Durham, North Carolina.
  • John P Kirkpatrick
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, United States of America.
  • Chunhao Wang
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC, United States.